A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

Summary

The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency and incontinence episodes.

Timeline

Start

2014-07-24

Primary completion

2015-10-29

Completion

2015-11-11

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

registry analysis (unspecified test); Mirabegron vs Tolterodine ER; p = 0.004; LS Mean Difference -2.89 (95% CI -4.86 to -0.93); ANOVA NCT02138747 ↗

Drugs

Indications